• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2025.20048

Clinical and biological features of chemoresistant locally advanced breast cancer

[Oncology]
Kazim Alievich Aliyev; Viktor Valentinovich Oleksenko; Evgeniya Yurievna Zyablitskaya; Anatoly Vladimirovich Kubyshkin;

Neoadjuvant chemotherapy (NCT) has currently become the standard for treating locally advanced breast cancer (LABC). LABC frequently develops resistance to cytostatics, thus limiting the NAC options. This article offers a view of a study into the prognostic value of clinical and biological factors in patients with Her2/neu-negative LABC featuring a resistant course; the study also implied analyzing the effectiveness of standard and dose-dense chemotherapy modes. The results show that the only predictor of the risk of developing refractoriness to ongoing NAC in LABC is the triple-negative biological subtype of the tumor. The use of taxanes (paclitaxel 175 mg/m2 once every 3 weeks) is associated with a significantly higher frequency of resistant forms in patients with luminal LABC (p=0.0069), which dictates the expediency of prioritizing anthracyclines as first-line therapy. Within the study in question, the use of dose-dense NCT modes did not lead to a reduction in the frequency of drug resistance development.

Download

References:
1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R. L. [et al.]. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024;74(3):229-263. https://doi.org/10.3322/caac.21834
2. Xiong X., Zheng L. W., Ding Y., Chen Y. F., Cai Y. W. [et al.]. Breast cancer: pathogenesis and treatments. Signal Transduct. Target. Ther. 2025;10(1):49. https://doi.org/10.1038/s41392-024-02108-4
3. Dhanushkodi M., Sridevi V., Shanta V., Rama R., Swaminathan R. [et al.]. Locally advanced breast cancer (LABC): Real-World outcome of patients from Cancer Institute, Chennai. JCO Global Oncology. 2021;7(7):767-781. https://doi.org/10.1200/GO.21.00001
4. Tyulyandin S. A., Artamonova E. V., Zhigulev A. N., Koroleva I. A., Parokonnaya A. A. [et al.]. Breast cancer. Practical recommendations RUSSCO, chapter 1.2. Zlokačestvennye opuholi. – Malignant tumors. 2023;13(3s2-1):157-200. (In Russ.). https://doi.org/10.18027/2224-5057-2023-13-3s2-1-157-200
5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxanecontaining chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277-1292. https://doi.org/10.1016/S0140-6736(23)00285-4
6. An J., Peng C., Tang H., Liu X., Peng F. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. Int. J. Mol. Sci. 2021;22(17):9644. https://doi.org/10.3390/ijms22179644
7. Khan M. M., Yalamarty S. S. K., Rajmalani B. A., Filipczak N.,Torchilin V. P. Recent strategies to overcome breast cancer resistance. Crit. Rev. Oncol. Hematol. 2024;197:104351. https://doi.org/10.1016/j.critrev-onc.2024.104351
8. Shchetinin E. V., Afanasyeva G. A., Sirak S. V., Shkodenko O. N., Neredko Yu. S. [et al.]. Immunotherapy of tumor diseases. Eksperimentalnaja i klinicheskaja farmakologija. –Experimental and clinical pharmacology. 2022;85(5):41-48. (In Russ.). https://doi.org/10.30906/0869-2092-2022-85-5-41-48
9. Vostretsova A. S., Buldakova T. I. Research of statistical methods of data analysis to assess the human condition. Matematicheskie metody v tekhnologiyakh i tekhnike. – Mathematical methods in technology and engineering. 2023:5;87-92. (In Russ.). https://doi.org/10.52348/2712-8873_MMTT_2023_5_87
10. Karim A. M., Eun Kwon J., Ali T., Jang J., Ullah I. [et al.]. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem. Pharmacol. 2023;212:115545. https://doi.org/10.1016/j.bcp.2023.115545
11. Kuo W. H., Chang Y. Y., Lai L. C., Tsai M. H., Hsiao C. K. [et al.]. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: A clinical study of triple-negative breast carcinomas. PLoS ONE. 2012;7:e45831. https://doi.org/10.1371/journal.pone.0045831
12. Yan Q., Deng Y., Zhang Q. A comprehensive overview of metaplastic breast cancer: Features and treatments. Cancer Sci. 2024;115(8):2506-2514.
https://doi.org/10.1111/cas.16208

Keywords: breast cancer, neoadjuvant chemotherapy, resistance, doxorubicin, carboplatin, paclitaxel